XLXiaomin Lu

Xiaomin Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaomin Lu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Lulu Sun

    Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.

    2 shared publications
  • Xiaona Zhang

    Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.

    2 shared publications
  • Xudong Wu

    State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Avenue, Nanjing 210023, China

    2 shared publications
  • Cunsi Shen

    Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

    1 shared publication
  • Cunsi Shen

    Jiangsu Key Laboratory of Pediatric Respiratory Disease, Affiliated Hospital of Nanjing University of Chinese Medicine

    1 shared publication
  • Gu Cheng

    Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Dual targeting of MAPK8 and JAK2 as a host-directed anti-inflammatory strategy for severe Klebsiella pneumoniae infection

    by Yang Zhang, Yanghao Lin, Kangkang Luo, Jingying Zhang, Yu Li, Ronghui Du, Hongwei Yi, Xiaomin Lu, Xudong Wu

    Severe Klebsiella pneumoniae empyema remains a therapeutic challenge because of complex host–pathogen interactions and frequent antibiotic failure. To dissect the underlying microenvironmental mechanisms and identify candidate therapeutics, we conducted a proof-of-concept single-patient study integrating longitudinal clinical multi-omics, single-cell spatial mapping, and virtual pharmacological screening. Untargeted metabolomics of pleural fluid revealed taurine-associated host-pathogen co-metabolism and identified a microbiota-specific reductase (K15373) as a computationally predicted metabolic vulnerability. Parallel transcriptomic network analysis identified a core signaling triad (MAPK8, JAK2, and TP53) associated with dysregulated inflammation, which was confirmed both in a K. pneumoniae lipopolysaccharide (LPS)-induced murine model of acute lung injury (ALI) and in longitudinal clinical pleural fluid samples. Projection of these targets onto a single-cell atlas of severe pulmonary infection revealed elevated expression in alveolar macrophages and type II pneumocytes, and a machine learning-based single-cell virtual knockout algorithm indicated that the hub genes contribute to cytokine release and epithelial barrier disruption. Network pharmacology and transcriptomic perturbation screening against large-scale databases then identified curcumin and evodiamine as candidate compounds that counteract the severe disease signature, and molecular dynamics simulations coupled with thermodynamic calculations predicted stable, high-affinity binding of curcumin to MAPK8 and of evodiamine to JAK2. We then evaluated the candidates in vivo in the K. pneumoniae LPS-induced murine ALI model. Given alone or in combination, curcumin and evodiamine attenuated body weight loss, pulmonary edema, alveolar-capillary barrier disruption, and histopathological injury. Western blot analysis showed that curcumin preferentially suppressed MAPK8/JNK phosphorylation, whereas evodiamine inhibited JAK2 phosphorylation, while combination therapy normalized both pathways; immunofluorescence revealed reduced infiltration of F4/80+ macrophages and Ly6G+ neutrophils. These results provide, to our knowledge, the first in vivo evidence that dual pharmacological inhibition of MAPK8 and JAK2 mitigates K. pneumoniae LPS-driven pulmonary inflammation. Overall, this computational systems biology approach characterizes the immunometabolic features of the infectious microenvironment and supports further medicinal chemistry optimization of curcumin- and evodiamine-based scaffolds as candidate dual-targeting agents, with particular attention to pharmacokinetic optimization and safety profiling.

  • Open Access

    Icariin prevents depression-like behaviors in chronic unpredictable mild stress-induced rats through Bax/cytoplasm C/caspase-3 axis to alleviate neuronal apoptosis

    by Xiao Wu, Xiaona Zhang, Lulu Sun, Xiaoming Lu, Cunsi Shen

    Major depressive disorder (MDD) affects approximately 16% of the global population. Our previous study has demonstrated that icariin (ICA) exhibits anti-depressant activity by increasing the expression of Brain-Derived Neurotrophic Factor (BDNF) in a rat model of chronic unpredictable mild stress (CUMS). In this study, we investigated whether and how ICA can prevent CUMS-induced depression-like behaviors in rats by modulating hippocampus neuronal apoptosis. Forty male rats were randomly divided into control, CUMS, CUMS-fluoxetine (Flx) (10 mg/kg), and CUMS-ICA (20 mg/kg) groups. Behavior tests including sucrose preference test (SPT), open field test (OFT), elevated plus-maze (EPM), and forced swimming tests (FST) were performed. The Nissl staining and TUNNEL assay were used to determine neuronal apoptosis. Subsequently, expression of the glucocorticoid receptor (GR), Bcl-2, cytochrome C, caspase-3 and Bax in the hippocampus was tested by western blot. Our results show that a chronic administration of ICA (20 mg/kg) can prevent CUMS-induced depressant-like behaviors in male model rats. Additionally, ICA significantly inhibited mitochondrial translocation of GR, reduced mitochondrial outer membrane permeabilization (MOMP) to suppress the release of cytochrome C, and then inhibit the activation of caspase-3. In conclusion, our research provides new evidence to understand the anti-depressant activity of ICA, which relates to its inhibition of neuronal apoptosis in the hippocampus through the mitochondrial apoptotic pathway.


  • Open Access

    Citrus alkaline extracts improve LPS-induced pulmonary fibrosis via epithelial mesenchymal transition signals

    by Li Junjie, Gu Cheng, Luo Kangkang, Li Yu, Yuan Zhiyao, Wu Xudong, Zhou Xianmei, Lu Xiaomin

    Background: Acute respiratory distress syndrome (ARDS) is a serious life threatening clinical critical illness. ARDS-related pulmonary fibrosis is a common complication of ARDS. The occurrence of early pulmonary fibrosis indicates a higher incidence and mortality of multiple organ failure. LPS-induced ARDS-related pulmonary fibrosis model in mice was established in this study. And we have explored the anti-pulmonary fibrosis effects and molecular mechanisms of the Citrus Alkaline Extracts (CAE) in vivo and in vitro. Methods: Pulmonary fibrosis mouse model and lung epithelial cell injury model were established in this study. H&E, Masson and Sirius Red staining were used to estimate lung tissue damage. Immunohistochemistry and western blotting were used to analyze proteins expression. Protein-protein interaction was observed by Co-Immunoprecipitation. Systemic impact of CAE on signaling pathway was examined by RNA-seq. Results: Through H&E, Masson and Sirius Red staining, it was convincingly indicated that therapeutic administration of CAE alleviated lung injury and fibrosis, while pretreated administration of CAE showed weak improvement. In vitro experiments showed that CAE had dual regulation to E-cadherin and N-cadherin, the important indicators of epithelial-mesenchymal transition (EMT). And it was further demonstrated that CAE reversed TGF-β1-induced EMT mainly through Wnt/β-catenin, Stat3/6 and COX2/PGE2 signals. Through RNA-Seq, we discovered important mechanisms by which CAE exerts its therapeutic effect. And network pharmacology analysis demonstrated core potential targets of CAE in EMT. Conclusion: Thus, this study provides new therapeutic effects of CAE in anti-fibrosis, and offers potential mechanisms for CAE in LPS-induced pulmonary fibrosis. Graphical


  • Open Access

    Icariin prevents depression-like behaviors in chronic unpredictable mild stress-induced rats through Bax/cytoplasm C/caspase-3 axis to alleviate neuronal apoptosis

    by Xiao Wu, Xiaona Zhang, Lulu Sun, Xiaomin Lu, Cunsi Shen

    Major depressive disorder (MDD) affects approximately 16% of the global population. Our previous study has demonstrated that icariin (ICA) exhibits anti-depressant activity by increasing the expression of Brain Derived Neurotrophic Factor (BDNF) in a rat model of chronic unpredictable mild stress (CUMS). In this study, we investigated whether and how ICA can prevent CUMS-induced depression-like behaviors in rats by modulating hippocampus neuronal apoptosis. Forty male rats were randomly divided into control, CUMS, CUMS-fluoxetine (Flx) (10 mg/kg), and CUMS-ICA (20 mg/kg) groups. Behavior tests including sucrose preference test (SPT), open field test (OFT), elevated plus-maze (EPM), and forced swimming tests (FST) were performed. The Nissl staining and TUNNEL assay were used to determine neuronal apoptosis. Subsequently, expression of glucocorticoid receptor (GR), Bcl-2, cytochrome C, caspase-3 and Bax in the hippocampus were tested by western blot. Our results show that a chronic administration of ICA (20 mg/kg) can prevent CUMS-induced depressant-like behaviors in male model rats. Additionally, ICA significantly inhibited mitochondrial translocation of GR, reduced mitochondrial outer membrane permeabilization (MOMP) to suppress the release of cytochrome C, and then inhibit the activation of caspase-3. In conclusion, our research provides new evidence to understand the anti-depressant activity of ICA, which relates to its inhibition of neuronal apoptosis in hippocampus through mitochondrial apoptotic pathway.


  • E-Prostanoid 2 Receptor Overexpression Promotes Mesenchymal Stem Cell Attenuated Lung Injury

    by Jibin Han, Xiaomin Lu, Lijuan Zou, Xiuping Xu, Haibo Qiu

    Mesenchymal stem cells (MSCs) represent a promising approach for the treatment of acute respiratory distress syndrome (ARDS). However, their low efficiency in homing to injured lung tissue limits their therapeutic effect. Prostaglandin E 2 (PGE 2 ) biosynthesis substantially enhances the inflammatory response of the tissue. Moreover, it also facilitates the migration of MSCs by activating the E-prostanoid 2 (EP2) receptor in vitro . Given these observations, it would seem reasonable that PGE 2 might act as a chemokine to promote the migration of MSCs through activation of the EP2 receptor. Herein, we confirmed that PGE 2 was significantly increased in lung tissue as a result of stimulation by LPS. In addition, we constructed a lentiviral vector carrying the EP2 gene, which was successfully transduced into MSCs (MSCs-EP2). Near-infrared imaging and immunofluorescence showed that compared with MSCs-GFP, MSCs-EP2 significantly enhanced MSC homing to injured lung tissue. Moreover, the diminished amounts of Evans blue in homogeneous lung parenchyma in vivo indicated, in comparison with MSCs-GFP, that MSCs-EP2 significantly decreased LPS-induced pulmonary vascular permeability. In addition, administration of MSCs-EP2 largely decreased the levels of interleukin-1β and tumor necrosis factor-α compared with that observed after administration of MSCs-GFP at both 24 and 72 hr. Our results suggested that treatment with MSCs-EP2 markedly enhanced MSC homing to damaged lung tissue and, in addition, improved both lung inflammation and permeability. Thus, MSCs and EP2 combination gene therapy could markedly facilitate MSC homing to areas of inflammation, representing a novel strategy for MSC-based gene therapy in inflammatory diseases.


  • Open Access

    The effect of benzodiazepines on insomnia in patients with chronic obstructive pulmonary disease: a meta-analysis of treatment efficacy and safety

    by Xiao-Min Lu, Ji-Ping Zhu, Xian-Mei Zhou

    Background: Insomnia is a common comorbidity associated with COPD. Although benzodiazepines (BZDs) can have adverse effects on respiratory response in COPD patients, these are the most common hypnotics. The aim of this study was to examine by meta-analysis the efficacy and safety of BZD to treat insomnia in COPD patients. Materials and methods: Electronic databases (PubMed, China National Knowledge Infrastructure, Cochrane clinical trials database) were searched. Studies were eligible if they compared the effects of BZD versus placebo on insomnia in COPD patients. Two reviewers extracted data independently. Disagreements were resolved by discussion with another reviewer until a consensus was achieved. Data that included objective and subjective sleep evaluation and respiratory function variables were extracted. Data were analyzed by the methods recommended by Review Manager 5.3 software. Results: A total of 233 records were identified through the initial search; of these, five studies were included in the meta-analysis. When BZD was compared with placebo, objective sleep quality was significantly improved, including total sleep time (95% confidence interval [CI] 0.54–1.14, PP P=0.001), and number of arousals/hour of sleep (95% CI -0.72 to -0.07, P=0.02). Otherwise, subjective sleep quality was not improved remarkably. Apart from maximum transcutaneous carbon dioxide pressure increase during sleep (95% CI 0.05–0.28, P=0.006), BZD administration had no effect on respiratory assessment. Conclusion: In this meta-analysis, the results suggested BZDs might be efficient and safe hypnotics. Compared with placebo, BZD improved sleep quality partly, and significantly increased maximum transcutaneous carbon dioxide pressure during sleep. More randomized controlled trials are necessary to determine the potential effect of BZD in COPD patients with insomnia.